Mohammad-Ali Jenabian

Mohammad-Ali Jenabian

Photo de Mohammad-Ali Jenabian
Téléphone : (514) 987-3000 poste 6794
Local : SB-3385
Langues : Français, Anglais, Persan
Liens d'intérêt
Informations générales

Cheminement académique

Depuis Juin 2018: Professeur Agregé, Immunologie et Virologie, Département des Sciences Biologiques, UQAM, Montréal, Québec, Canada.

2014-2018: Professeur Adjoint, Immunologie et Virologie, Département des Sciences Biologiques, UQAM, Montréal, Québec, Canada.

2011-2014: Chercheur Postdoctoral, Immunologie Clinique, Institut de recherche du Centre universitaire de santé McGill, Université McGill, Montréal, Québec, Canada.

2009-2011: Chercheur Postdoctoral, Immunologie Fondamentale, Institut Mondor de Recherche Biomédicale (INSERM U955), Université Paris-Est Créteil (Paris XII), Paris, France.

2009: Docteur ès Sciences (Ph.D.), Virologie, Centre de Recherche Biomédicale des Cordeliers (INSERM U743) et Hôpital Européen Georges-Pompidou, Université Pierre et Marie Curie (Paris VI), Paris, France.

2003: Docteur en Médicine Vétérinaire (D.V.M.), Faculté de Médicine Vétérinaire, Université de Karaj, Karaj, Iran.

Projets de recherche en cours

Partenaires (organismes, entreprises)

  • Membre du comité exécutif, Réseau Sida et Maladies Infectieuses, Le Fonds de recherche du Québec - Santé (FRQ-S)
  • Membre régulier, Réseau de Thérapie Cellulaire et Tissulaire, (ThéCell), Le Fonds de recherche du Québec - Santé (FRQ-S)
  • Membre régulier, Réseau Canadien pour les essais VIH des IRSCs (CTN)
  • Co-chercheur, Consortium canadien de recherche sur la guérison du VIH (CanCURE)
  • Membre régulier, Réseau intersectoriel de recherche en santé de l'Université du Québec(RISUQ)
  • Membre régulier, Centre d'Excellence en Recherche sur les Maladies Orphelines - Fondation Courtois (CERMO-FC)

Affiliations externes principales

Services à la collectivité

- Membre, Comité institutionnel de protection des animaux (CIPA)
- Délégué universitaire de l'UQAM aux instituts de recherche en santé du Canada (IRSCs)

Directions de thèses et mémoires

Thèses de doctorat


Articles scientifiques
  • Iannello, A., Samarani, S., Allam, O., et al. (2017). A potentially protective role of IL-18 Binding Protein in HIV-infected Long-Term Non-Progressors. Cytokine, 90, 96–99.
  • Allam, O., Samarani, S., Jenabian, M.-A., et al. (2017). Differential synthesis and release of IL-18 and IL-18 Binding Protein from human platelets and their implications for HIV infection. Cytokine, 90, 144–154.
  • Mossoro-Kpinde, C.D., Mboumba Bouassa, R.-S., Jenabian, M.-A., et al. (2016). Analytical Performances of Human Immunodeficiency Virus Type 1 RNA-Based Amplix® Real-Time PCR Platform for HIV-1 RNA Quantification. AIDS Research and Treatment, 2016, Article ID 7954810.
  • Huang, Y., Hoque, M.T., Jenabian, M.-A., et al. (2016). Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. Journal of Antimicrobial Chemotherapy, 71(7), 1954–1965.
  • Ahmad, A., Mehraj, V., Jenabian, M.-A., Samarani, S., Tremblay, C. et Routy, J.-P. (2016). Combination antiretroviral therapy and indoleamine 2,3-dioxygenase in HIV infections: challenges and new opportunities. AIDS, 30(11), 1839–1841.
  • Aounallah, M., Dagenais-Lussier, X., El-Far, M., et al. (2016). Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. Cytokine & Growth Factor Reviews, 28, 1–10.
  • Mossoro-Kpinde, C.D., Jenabian, M.-A., Gody, J.C., et al. (2016). Evaluation of the Upgraded Version 2.0 of the Roche COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Qualitative Assay in Central African Children. Open AIDS Journal, 10, 158–163.
  • Samarani, S., Allam, O., Sagala, P., et al. (2016). Imbalanced production of IL-18 and its antagonist in human diseases, and its implications for HIV-1 infection. Cytokine, 82, 38–51.
  • Jenabian, M.-A., Costiniuk, C.T., Mehraj, V., et al. (2016). Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. AIDS, 30(18), 2777–2786.
  • Jenabian, M.-A., Mehraj, V., Costiniuk, C.T., et al. (2016). Influence of Hepatitis C Virus Sustained Virological Response on Immunosuppressive Tryptophan Catabolism in ART-Treated HIV/HCV Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes, 71(3), 254–262.
  • Wacleche, V.S., Goulet, J.-P., Gosselin, A., et al. (2016). New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 13(59).
  • Mehraj, V., Jenabian, M.-A., Ponte, R., et al. (2016). The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS, 30(10), 1617–1627.
  • Routy, J.-P., Angel, J., Patel, M., et al. (2015). Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Medicine, 16(1), 48–56.
  • Routy, J.-P., Mehraj, V., Vyboh, K., Cao, W., Kema, I. et Jenabian, M.-A. (2015). Clinical Relevance of Kynurenine Pathway in HIV/AIDS: An Immune Checkpoint at the Crossroads of Metabolism and Inflammation. AIDS Reviews, 17(2), 96–106. Récupéré de
  • Hubert, A., Subra, C., Jenabian, M.-A., et al. (2015). Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+ Patients: Correlations With Known Markers of Disease Progression. Journal of Acquired Immune Deficiency Syndromes, 70(3), 219–227.
  • Vyboh, K., Jenabian, M.-A., Mehraj, V. et Routy, J.-P. (2015). HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets. Journal of Immunology Research, 2015, Article ID 614127.
  • Costiniuk, C.T. et Jenabian, M.-A. (2015). HIV reservoir dynamics in the face of highly active antiretroviral therapy. AIDS Patient Care and STDs, 29(2), 55–68.
  • Cleret-Buhot, A., Zhang, Y., Planas, D., et al. (2015). Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology, 12(102).
  • Jenabian, M.-A., El-Far, M., Vyboh, K., et al. (2015). Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection. The Journal of Infectious Diseases, 212(3), 355–366.
  • DaFonseca, S., Niessl, J., Pouvreau, S., et al. (2015). Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology, 12(38).
  • Jenabian, M.-A., Talla, F., Talla, P., et al. (2015). Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays. Nigerian Medical Journal, 56(6), 420–424.
  • Trottier, B., Galanakis, C., Longpré, D., et al. (2015). Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). HIV Clinical Trials, 16(3), 111–116.
  • Jenabian, M.-A., Costiniuk, C.T., Mboumba Bouassa, R.S., Chapdeleine Mekue Mouafo, L., Brogan, T.V. et Bélec, L. (2015). Tackling virological failure in HIV-infected children living in Africa. Expert Review of Anti-infective Therapy, 13(10), 1213–1223.
  • LeGoff, J., Roques, P., Jenabian, M.-A., et al. (2015). Variability of human immunodeficiency virus-1 in the female genital reservoir during genital reactivation of herpes simplex virus type 2. Clinical Microbiology and Infection, 21(9), 873.e1–873.e9.
  • Costiniuk, C.T. et Jenabian, M.-A. (2014). Cell-to-cell transfer of HIV infection: implications for HIV viral persistence. The Journal of General Virology, 95(Pt 11), 2346–2355.
  • Carriere, M., Lacabaratz, C., Kok, A., et al. (2014). HIV "elite controllers" are characterized by a high frequency of memory CD8+ CD73+ T cells involved in the antigen-specific CD8+ T-cell response. The Journal of Infectious Diseases, 209(9), 1321–1330.
  • Mehraj, V., Jenabian, M.-A., Vyboh, K. et Routy, J.-P. (2014). Immune Suppression by Myeloid Cells in HIV Infection: New Targets for Immunotherapy. Open AIDS Journal, 8, 66–78.
  • Costiniuk, C.T., Sigal, A., Jenabian, M.-A., Nijs, P. et Wilson, D. (2014). Short communication: Lower baseline CD4 count is associated with a greater propensity toward virological failure in a cohort of South African HIV patients. AIDS Research and Human Retroviruses, 30(6), 531–534.
  • Jenabian, M.-A., Patel, M., Kema, I., et al. (2014). Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clinical and Experimental Immunology, 178(1), 102–111.
  • Costiniuk, C.T. et Jenabian, M.-A. (2014). The lungs as anatomical reservoirs of HIV infection. Reviews in Medical Virology, 24(1), 35–54.
  • Lebouché, B., Jenabian, M.-A., Singer, J., et al. (2014). The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial. Trials, 15(390).
  • Moussa, S., Jenabian, M.-A., Gody, J.C., et al. (2013). Adaptive HIV-specific B cell-derived humoral immune defenses of the intestinal mucosa in children exposed to HIV via breast-feeding. PLoS One, 8(5).
  • Jenabian, M.-A., Patel, M., Kema, I., et al. (2013). Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One, 8(10).
  • Koyalta, D., Jenabian, M.-A., Djouater, B., et al. (2013). Field evaluation in Chad of community usage of CD4 T lymphocyte counting by alternative single-platform flow cytometry. BMC Health Services Research, 13(373).
  • Jenabian, M.-A., Nicolette, C.A., Tcherepanova, I.Y., Debenedette, M.A., Gilmore, N. et Routy, J.-P. (2013). Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 64(4), 345–350.
  • Jenabian, M.-A., Seddiki, N., Yatim, A., et al. (2013). Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathogens, 9(4).
  • Koyalta, D., Jenabian, M.-A., Nadjiouroum, N., et al. (2013). Single-platform, volumetric, CD45-assisted pan-leucogating flow cytometry for CD4 T lymphocytes monitoring of HIV infection according to the WHO recommendations for resource-constrained settings. BMC Research Notes, 6(169).
  • Bernier, A., Cleret-Buhot, A., Zhang, Y., et al. (2013). Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology, 10(160).
  • Jenabian, M.-A., Ancuta, P., Gilmore, N. et Routy, J.-P. (2012). Regulatory T cells in HIV infection: can immunotherapy regulate the regulator? Clinical and Developmental Immunology, 2012, Article ID 908314.
  • Saidi, H., Jenabian, M.-A. et Belec, L. (2012). Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. AIDS Research and Human Retroviruses, 28(11), 1485–1497.
  • Nikolova, M., Carriere, M., Jenabian, M.-A., et al. (2011). CD39/adenosine pathway is involved in AIDS progression. PLoS Pathogens, 7(7).
  • Belec, L., Jenabian, M.-A., Charpentier, C. et Saidi, H. (2011). Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiology, 6(7), 731–737.
  • Charpentier, C., Koyalta, D., Ndinaromtan, M., et al. (2011). Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. Journal of Infection in Developing Countries, 5(1), 64–67.
  • Charpentier, C., Jenabian, M.-A., Piketty, C., et al. (2011). Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scandinavian Journal of Infectious Diseases, 43(5), 373–379.
  • Auvert, B., Jenabian, M.-A., Saidi, H., Lissouba, P. et Belec, L. (2011). Partial inactivation of CCR5- and CXCR4- tropic HIV-1 by human urine. Archives of Virology, 156(12), 2181–2186.
  • Jenabian, M.-A., Saidi, H., Charpentier, C., et al. (2010). Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Research and Therapy, 7(16).
  • Jenabian, M.-A., Auvert, B., Saidi, H., Lissouba, P., Matta, M. et Belec, L. (2010). Potent in vitro inactivation of both free and cell-associated CCR5- and CXCR4-tropic HIV-1 by common commercial soap bars from South Africa. Journal of Acquired Immune Deficiency Syndromes, 54(4), 340–342.
  • Metlas, R.M., Srdic, T.V., Jenabian, M.-A., et al. (2009). Immunoglobulin G-reactive antibodies from sera of healthy individuals enriched in IgG2--therapeutic potential in HIV-1 infection. Current HIV Research, 7(4), 378–383.
  • Jenabian, M.-A., Saidi, H., Charpentier, C., et al. (2009). In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). The Journal of Antimicrobial Chemotherapy, 64(6), 1192–1195.
  • Eslahpazir, J., Jenabian, M.-A., Bouhlal, H., et al. (2008). Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clinical and Vaccine Immunology (CVI), 15(5), 872–884.
  • Saidi, H., Jenabian, M.-A., Gombert, B., Charpentier, C., Mannarini, A. et Belec, L. (2008). Pre-clinical development as microbicide of zinc tetra-ascorbo-camphorate, a novel terpenoid derivative: potent in vitro inhibitory activity against both R5- and. AIDS Research and Therapy, 5(10).
  • Saidi, H., Nasreddine, N., Jenabian, M.-A., et al. (2007). Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins: implication for microbicide development. Journal of Translational Medicine, 5(28).